Ann Arbor, Michigan - Upkara, a leading biotechnology company based in Ann Arbor, Michigan, announced today the successful completion of its Series A funding round, raising an impressive $9 million. The round was led by Origin, a prominent venture capital firm specializing in investments in the biotechnology sector.

Upkara is revolutionizing the field of biopreservation through the development of novel technologies. These innovative solutions are designed to stabilize a wide range of biopharmaceuticals, including proteins, nucleic acids, viruses, and cells.

Upkara's groundbreaking technology has broad applications and holds significant potential within various sectors, such as analytical testing, diagnostic testing, and human medicine markets. The company aims to achieve global commercialization by eliminating the need for cold-chain requirements, thereby enabling the safe and efficient delivery of life-saving medicines worldwide.

"Upkara's mission is to make a meaningful impact on society by providing advanced biopreservation technologies that overcome the challenges associated with medical storage in regions lacking critical infrastructure," said Alan Turfe, Founder of Upkara. "With the support of Origin and our esteemed investors, we are confident in our ability to deliver innovative solutions that will transform the biopharmaceutical industry."